drugset / Trial / NCT05864144
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2
Active not recruiting
98 enrolled
Sensei Biotherapeutics, Inc.
Regeneron Pharmaceuticals · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
Timeline
- Start
- 2023-05-31
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | — | Intravenous |
| Subject | SOLNERSTOTUG | Monoclonal antibody | — | Intravenous |
Indications
breast cancer
cervical cancer
colorectal cancer
cutaneous neuroendocrine carcinoma
esophageal cancer
gastric cancer
head and neck cancer
kidney cancer
malignant pancreatic neoplasm
melanoma
metastatic malignant neoplasm
non-small cell lung carcinoma
ovarian cancer
prostate cancer
refractory malignant neoplasm
sarcoma
thyroid cancer
urinary bladder cancer